Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Boston University · University of Maryland, Baltimore · +1 more institution
Abstract
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy and coronary artery calcification are potent risk factors for mortality in CKD, and FGFs have been implicated in the pathogenesis of both myocardial hypertrophy and atherosclerosis. We conducted a cross-sectional study to test the hypothesis that elevated FGF-23 concentrations are associated with left ventricular hypertrophy and coronary artery calcification in patients with CKD. METHODS AND RESULTS: In this study, 162 subjects with CKD underwent echocardiograms and computed…
Citation impact
- FWCI
- 26.91
- Percentile
- 100%
- References
- 47
Authors
13- OMOrlando M. GutiérrezCorresponding
Boston University, University of Maryland, Baltimore
- JLJames L. Januzzi
Boston University, University of Maryland, Baltimore, University of Miami
- TITamara Isakova
Boston University, University of Maryland, Baltimore, University of Miami
- KLKaren Laliberte
Boston University, University of Maryland, Baltimore, University of Miami
- KSKelsey Smith
Boston University, University of Maryland, Baltimore, University of Miami
Topics & keywords
- Medicine
- Left ventricular hypertrophy
- Fibroblast growth factor 23
- Internal medicine
- Cardiology
- Kidney disease
- Odds ratio
- Muscle hypertrophy
- Good health and well-being